drugset / Trial / NCT05619913
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Phase 2
Recruiting
30 enrolled
Australia New Zealand Gynaecological Oncology Group
Eisai Inc. · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizumab.
Timeline
- Start
- 2023-05-22
- Primary completion
- 2025-03
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |